PP
OCUL icon

Paloma Partners’s Ocular Therapeutix OCUL Stock Holding History

Paloma Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,879
Closed -$55K – 1827
2019
Q4 		$55K Buy
+13,879
New +$48.3K ﹤0.01% 2077
2017
Q1 		– Sell
-13,023
Closed -$109K – 2158
2016
Q4 		$109K Buy
+13,023
New +$101K ﹤0.01% 1904

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's OCUL Position: Q1 2020 in Review

Paloma Partners sold out of Ocular Therapeutix (OCUL) in Q1 2020, closing a stake of 13,879 shares — an estimated $55K sold.

Paloma Partners first reported a position in OCUL in Q4 2016 and held it in 2 quarters. The position peaked at $109K in Q4 2016. 90 funds tracked by Wall St. Rank hold OCUL as of Q1 2020.

  • Paloma Partners reported no remaining Ocular Therapeutix position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 13,879 Ocular Therapeutix shares in Q1 2020, an estimated $55K.
  • Paloma Partners first reported a position in Ocular Therapeutix in Q4 2016 and held it in 2 quarters.
  • Paloma Partners's Ocular Therapeutix position peaked at $109K in Q4 2016.
  • 90 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.